QRX-3 for Chronic Kidney Disease Progression
This study is looking at a new drug called QRX-3 to see if it can help prevent and treat the worsening of chronic kidney disease (CKD), acute kidney injury, and kidney failure. QRX-3 is a capsule designed to improve how your kidney cells work by helping with a process called NAD/NAD+ redox pathway. We are looking for 3000 adults, aged 18 to 90, who have chronic kidney disease with a specific level of kidney function (eGFR less than 60mls/min) and a slow decline in their kidney function over the past year. The main goal is to see if QRX-3 can improve your kidney function, measured by your Glomerular filtration rate (eGFR), after one year. The current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. The phase of the study is not specified, and it plans to enroll 3000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 1 year, suggesting participants will be followed for at least this duration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- change in Glomerular filtration rate1 year
change percentage in kidney function level measured with cystatin creatinine glomerular filtration rate